Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Northstar49on Feb 25, 2020 11:29am

107 Views

Post# 30730925

RE:RE:100% DELAYED

No one called any clinic, a liar they are. Confidentiality to all Clients, is the law. You will not get any information unless you are in the loop, it's all bull Sh!t. Insider they are not!!!

Those so called frendly people are trying to bring down the share price, shorters they are.
Information I can gather, these pills are going to stand out in the market. Will they change the world time will tell.

If you do not believe just get out. Let the rest of us make some good money.

Long I am. Stay Thirsty All.

See you $$.$$

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal